Conclusions
Ruxilitinib therapy is effective in suppressing IE, which is one of the
main risk factors potentially leading to primary and secondary severe
graft failure. Therefore, this kind of therapy is promising for
preparing pediatric patients with TM and pronounced IE for HSCT.